ALK and non-small cell lung carcinoma: The findings of this retrospective study of patients with EGFR/ALK-wild-type, metastatic nonsquamous NSCLC treated with first-line pembrolizumab-combination therapy serve to illustrate outcomes achieved in the real-world setting of community oncology practice in the US for patients with good performance status.